Combination of an anti-ED - B fibronectin domain antibody - IL-2 fusion protein and gemcitabine

摘要

The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.